Overview
- Fulcrum announced on Monday that it has stopped development of pociredir, its lead sickle-cell candidate, and opened a comprehensive strategic review of options including a possible sale or merger.
- The company said the decision followed FDA end-of-phase feedback, which cited the global March withdrawal of Ipsen’s tazemetostat and concluded that drugs acting on the PRC2 complex may share a malignancy risk.
- Pociredir had shown dose-dependent increases in fetal hemoglobin and early signs of clinical benefit in a Phase 1b trial, but Fulcrum and the FDA noted earlier preclinical malignancy signals tied to the program.
- Investors reacted sharply: Fulcrum’s shares fell about 50% in after-hours and premarket trading, and the company said it will cut operating expenses and preserve cash while the board evaluates next steps.
- Fulcrum reported $333.3 million in cash and marketable securities as of March 31, but the move raises broader regulatory and investment uncertainty for PRC2-targeted and other sickle-cell therapies and may slow patient access to new oral options.